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Background: The expression of CD204 on macrophages in the 
stroma of the primary tumor is reportedly correlated with an unfavor-
able prognosis for lung cancer. The purpose of this study is to investi-
gate the correlation among the number of CD204+ tumor–associated 
macrophages infiltrating the stroma of the primary tumor, the number 
of circulating CD14+CD204+ cells from the pulmonary vein (PV), and 
recurrence-free probability in non–small-cell lung cancer patients.
Methods: Human mononuclear cells were isolated from the PV of 
resected lungs. We examined the expressions of CD14 and CD204 
on these cells by flow cytometry. Immunohistochemical staining for 
CD204 was performed in the resected specimens.
Results: The number of CD14+CD204+ cells from the PV was found 
to be correlated with the number of CD204+ tumor–associated mac-
rophages identified in the stroma of the tumor. Significantly more 
cases with high levels of CD14+CD204+ cells from the PV were 
found to have developed early recurrences. CD14+CD204+ cells, 
which were polarized to the tumor-promoting phenotype cultured 
in lung cancer cell line–conditioned medium, facilitated the lung 
metastasis of cancer cells more effectively than CD14+CD204− cells 
in our in vivo mouse model. In multivariate analysis, only the high 
number of CD14+CD204+ cells from the PV was found to be a statis-
tically significant independent risk factor for early recurrence.
Conclusion: Our results showed the possibility that circulating 
CD14+CD204+ cells contribute to the metastasis of cancer cells. 
The blockage of circulating CD14+CD204+ cells activity may pre-
vent postoperative recurrence in resected non–small-cell lung can-
cer patients.
Key Words: Tumor-associated macrophages, CD204, Lung cancer, 
Metastasis, Adjuvant therapy.
(J Thorac Oncol. 2014;9: 179–188)
Lung cancer is the leading cause of cancer death in the world.1 Although the most effective treatment for patients 
with early-stage lung cancer is surgical resection, a consider-
able number of tumors have been observed to recur even after 
complete resection. Local recurrence after complete resection 
is in fact quite low, whereas distant recurrences occur more 
frequently.2 These recurrences typically lead to postoperative 
cancer-related death.
Solid tumors comprised cancer cells, nonmalignant stro-
mal cells, and migratory hematopoietic cells. Complex interac-
tions between noncancer cells and cancer cells are crucial, and 
evidence has shown that stromal cells interfere with the pro-
liferation, differentiation, and invasion of cancer cells.3–5 One 
type of stromal cell which is involved in promoting tumor pro-
gression is the macrophage.6–10 Bone marrow–derived circulat-
ing myelomonocytic CD14-positive (CD14+) cells have been 
reported to infiltrate tumors and are commonly referred to as 
 tumor-associated macrophages.11 These cells receive various 
signals from diverse cells in the tumor tissue, and some of these 
cells are polarized to a tumor-promoting phenotype.10,11 Thus far, 
several lines of evidence have indicated that the  tumor-promoting 
phenotype of macrophages expresses high levels of a scaven-
ger receptor known as CD204.11 The expression of CD204 on 
macrophages in the stroma of the primary tumor is reportedly 
correlated with an unfavorable prognosis for cancer in several 
organs.12–14 We have also previously reported that the infiltration 
of CD204+ macrophages into the stroma of the primary tumor 
tissue is correlated with an unfavorable postoperative prognosis 
in patients with completely resected non–small-cell lung cancer 
(NSCLC).15,16 However, there remains one question regarding 
the cause of the unfavorable postoperative prognosis of patients 
with a large number of CD204+ macrophages infiltrating the 
resected primary tumor tissue: why do postoperative recurrences 
develop more frequently in such patients even though their can-
cers have been completely resected? To answer this question, 
we investigated the correlation among the number of CD204+ 
macrophages infiltrating the stroma of the primary tumor, the 
number of circulating CD14+CD204+ cells, and the probability 
of postoperative recurrences in NSCLC patients.
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MATERIALS AND METHODS
Cell Lines and Cell Cultures
A549 were obtained from the RIKEN BioResource Center 
(Tsukuba, Japan) and were cultured in Dulbecco's Modified 
Eagle Medium (DMEM) (Sigma, St. Louis, MO). CRL-5807 
was obtained from the American Type Culture Collection 
(ATCC, Manassas, VA) and was cultured in Roswell Park 
Memorial Institute medium 1640. All the cell lines were cul-
tured in a medium containing 10% fetal bovine serum (Sigma) 
and 1% penicillin and streptomycin (Sigma) and were incubated 
at 37°C in an atmosphere containing 5% carbon dioxide.
Patient Samples
Normal fibroblasts were obtained from the surgically 
resected lungs of patients with lung cancer as previously 
reported.17 Human mononuclear cells were isolated from the 
pulmonary artery (PA) or pulmonary vein (PV) of resected lungs 
by using BD Vacutainer Evacuated Blood Collection Tubes (BD 
Bioscience, Inc., San Jose, CA) according to the manufacture’s 
instructions. In this study, a 21-gauge needle was inserted into 
the PA and PV that had been surgically resected from primary 
lung cancer patients at our hospital; the blood within the PA and 
PV was then collected into tubes. After centrifugation, blood 
mononuclear cell layers in the tubes were collected and counted. 
Human CD14+ cells were isolated using anti-CD14 microbeads 
(Miltenyi Biotec, Tokyo, Japan). CD14 cells were seeded on 
RepCell (a  temperature-responsive cell culture dish; CellSeed 
Inc., Tokyo, Japan) at a density of 1.5 × 105/cm2 and cultured 
in DMEM or lung cancer cell line–conditioned or fibroblast-
conditioned medium. After 3 to 7 days, the cells were detached 
by lowering the temperature of the RepCell down to 20°C for 30 
minutes, and the cells were harvested.
Flow Cytometry
The expression of cell surface antigens was determined using 
two-color immunofluorescence staining. In brief, 100 μl of blood 
mononuclear cells (containing 5 × 105 cells) was incubated with 40 
μl of FcR-blocking reagent (MBL, Aichi, Japan) for 10 minutes to 
inhibit nonspecific bindings. For double CD14 or CD204 labeling, 
cells were stained with 10 μg/ml of fluorescein isothiocyanate–
conjugated CD14 (eBioscience, San Diego, CA) mAb, and 5 μg/
ml of CD204 (R&D Systems,  Wiesbaden-Nordenstadt, Germany) 
mAb labeled with Alexa Fluor 555 (Invitrogen, Carlsbad, CA). 
Fluorescein isothiocyanate–conjugated and Alexa Fluor 555 
labeling isotype–matched immunoglobulin Ig-G1 (Abcam, 
Cambridge, United Kingdom) and IgG2a (DakoCytomation, 
Hamburg, Germany) antibodies were used as negative controls. 
A florescence activated cell sorter (FACS) analysis was performed 
using a FACSCalibur flow cytometer (BD Bioscience, Heidelberg, 
Germany). The CD14+CD204− cells and the CD14+CD204+ cells 
were sorted using FACSAria (BD Biosciences).
Antibodies and Immunohistochemistry
The block containing the most extensive tumor compo-
nent was selected from each specimen. Sections (4 μm each) 
were cut from the paraffin blocks and mounted on silanized 
slides. Individual slides were immunostained using mouse 
anti-human CD204 antibody (Scavenger Receptor class A-E5; 
Transgenic, Kumamoto, Japan) at a dilution of 1:100. Round 
cells in the stroma of the cancer tissue were counted as macro-
phages. Two pathologists (R.M. and G.I.) counted the CD204-
positive macrophages under high-power microscopic fields 
(×400; 40× objective and 10× ocular; 0.196 mm2/field), on the 
basis of the methodology used in a previous report.15,16
In Vitro Matrigel Invasion Assay
The invasive capacity of cancer cells was assessed using a 
matrigel invasion assay. In brief, the upper surface of a filter (pore 
size, 8.0 μm; BD Bioscience) was coated with basement mem-
brane matrigel. A total of 2.5 × 104 A549 cells were added to the 
upper chamber and incubated for 22 hours. After incubation, the 
remaining cells on the upper surface of the filters were removed 
by wiping with cotton swabs, and the invading cells on the lower 
surface were fixed in 10% formalin and stained with hematoxylin 
and eosin. The cells that had migrated from the upper to the lower 
side of the filter were counted under a light microscope.
Evaluation of Lung Tumors
Six-week-old female severe combined immunodeficient 
mice (C.B-17 background) were purchased from CLEA JAPAN, 
Inc. (Tokyo, Japan) and maintained at the National Cancer Center 
Research Institute East (Chiba, Japan). All the animals were 
maintained under specific-pathogen-free, temperature-controlled 
environmental conditions throughout the study, in accordance 
with institutional guidelines. Written approval for all the animal 
experiments was obtained from the local Animal Experiments 
Committee of the National Cancer Center Research Institute.
All the injections were administered through the tail vein. 
We injected 5 × 104 cancer cells into the tail vein of each mouse 
and killed the mice 30 days later. To determine the tumor inci-
dence and multiplicity, whole lungs were manually inflated with 
and fixed in 4% paraformaldehyde for at least 24 hours and then 
embedded in paraffin. Paraffin-embedded lungs were serially 
sectioned at 4 μm and were histologically examined using hema-
toxylin and eosin–stained sections, as previously described.18
Microarray Analysis
We used GeneChip Human Genome U133 Plus 2.0 
arrays (Affymetrix, Santa Clara, CA), containing 54,675 
probe sets, to analyze the mRNA expression levels of 
approximately 47,000 transcripts and variants from 38,500 
 well-characterized human genes. Target cRNA was gener-
ated from 100 ng of total RNA from each sample using a 3' 
IVT Express Kit (Affymetrix). The arrays were scanned using 
a GeneChip Scanner 3000 (Affymetrix), and the intensity 
of each feature of the array was calculated using GeneChip 
Operating Software, version 1.1.1 (Affymetrix). The average 
intensity was standardized to the target intensity, which was 
set equal to 1000, to reliably compare various multiple arrays. 
The values were log transformed and median centered. The 
programs GeneSpring (Agilent Technologies, Santa Clara, 
CA) and Excel (Microsoft, Redmond, WA) were used to per-
form the numerical analysis to permit gene selection.
181Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 2, February 2014 Circulating CD14+CD204+ Cells
Statistical Analysis
All the data were presented as the mean ± standard error. 
Continuous variables were compared using unpaired t tests. The 
length of the recurrence-free period was calculated in months 
from the date of resection to the date of the first recurrence 
or the last follow-up. To calculate recurrence-free probability, 
patients who died without recurrence or who were known to 
be recurrence-free at the date of last contact were censored. 
For univariate analyses, all cumulative survival rates were 
estimated using the Kaplan–Meier method and differences in 
variables were determined using the  log-rank test. Multivariate 
analyses were performed using Cox’s proportional hazard 
regression model. All p values reported were two-sided, and 
the significance level was set at less than 0.05. Analyses were 
performed using the statistical software SPSS 11.0 (Dr. SPSS 
II for Windows, standard version 11.0; SPSS Inc., Chicago, 
IL). This study was conducted as part of a National Cancer 
Center institutional review board–approved protocol.
FIGURE 1.  Cell surface protein expres-
sion of CD204 on CD14+ cells from 
PA cultured in lung cancer cell line–
conditioned medium. A, Blood samples 
from ligated PA of surgically resected 
lungs. Change in cell surface protein 
expressions of CD204 on CD14+ cells 
as determined using flow cytometry. 
B, Blood samples from ligated PA of 
surgically resected lungs. Change in cell 
surface protein expressions of CD204 
on CD14+ cells as determined using 
flow cytometry. B,Change in CD204 
cells per CD14 cell ratio (n = 4 for each 
group). *Compared with cases cultured 
in fibroblast-conditioned medium (all, 
p < 0.05). PA, pulmonary artery; FITC, 
fluorescein isothiocyanate.
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RESULTS
Cell Surface Protein Expression of CD204 
on CD14+ Cells from PA Cultured in Lung 
Cancer Cell Line–Conditioned Medium
Blood samples were obtained from the dissected and 
ligated PA (an inflow tract) of surgically resected lungs 
(Fig. 1A), and CD14+ monocytes were isolated using  anti-CD14 
microbeads. Because CD204 is the best-known marker of the 
tumor-promoting phenotype of tumor-associated macrophages, 
we assessed the changes in the cell surface expression of CD204 
occurring on the surface of CD14+ cells cultured in lung cancer 
cell line–conditioned medium. CD14+ cells isolated from the 
PA were not completely negative for CD204 expression, and 
FIGURE 2.  Correlation among the number of CD204+ macrophages infiltrating the stroma of the primary tumor and the 
recurrence-free probability in stage I adenocarcinoma patients. A, Immunohistochemical staining for CD204 in lung cancer 
specimens. The sections were obtained from tumor specimens with low or high levels of CD204+ cells. B, Significantly more 
cases with a high number of CD204+ macrophages develop early recurrence within 3 years after resection (p < 0.01).C, CD204+ 
macrophages are found not only in the stroma of the tumor but also in intratumoral blood vessels. H.E., hematoxylin and eosin 
staining (×200); VVG, Victoria blue van Gieson staining (×200); CD204, CD204 staining (×200).
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the expression varied among different patients (8.5% ± 2.0%). 
During a 72-hour culture in  CRL5807-conditioned medium, 
CD204 expression on the CD14+ cells increased significantly 
(Fig. 1A). Although the levels of CD204 expression were 
observed to differ among these two media conditioned with 
different lung cancer cell lines, the expression on CD14+ cells 
had increased significantly after culture in lung cancer cell 
line–conditioned media (Fig. 1A). In contrast, culturing the 
CD14+ cells in the normal fibroblast-conditioned medium did 
not induce the expression of CD204 on CD14+ cells during 
a 72-hour time course (Fig. 1B). From these results, we con-
cluded that the expression of CD204 on CD14+ cells is a useful 
marker for the detection of CD14+ cells affected by cancer cells.
Correlation between the Number of 
CD204+ Macrophages Infiltrating the 
Stroma of the Primary Tumor and the 
Recurrence-Free Probability in Resected 
Stage I Lung Adenocarcinoma Patients
We performed immunohistochemical staining for 
CD204 in 207 consecutive stage I lung adenocarcinoma 
patients who underwent complete resection between January 
2004 and December 2006 and counted the number of CD204+ 
macrophages in the stroma of the tumor under a high-power 
microscopic field (×400), as previously reported.15,16 The 
median count for all 207 stage I adenocarcinoma patients was 
8, with an interquartile range of 0 to 77. Representative tissue 
specimens are shown in Figure 2A for tumors with low and 
high levels of CD204+ macrophages. Patients were classified 
into two groups according to whether they had high (>8) or 
low (≤8) levels of CD204+ macrophages, based on the median 
number of CD204+ macrophages for the entire group.
Table 1 lists the 3-year recurrence-free probabili-
ties according to clinicopathological features. The 3-year 
 recurrence-free probability for cases with high levels of CD204+ 
macrophages was significantly lower than that for cases with 
low levels (82.1% and 98.0%, respectively; p < 0.01; Fig. 2B).
As shown in Figure 2C, CD204+ macrophages were 
found not only in the stroma of the tumor but also in the 
intratumoral blood vessels. Because this finding may indicate 
that CD204+ macrophages exist not only in the stroma of the 
primary tumor but also in bloodstream and circulate through-
out the body, we next examined the number of circulating 
CD14+CD204+ cells from the PV (an outflow tract).
Correlation among the Number of CD204+ 
Macrophages Infiltrating the Stroma of the 
Primary Tumor, the Number of CD14+CD204+ 
Cells from the PV, and the Recurrence-Free 
Probability in Resected NSCLC Patients
We examined the number of CD14+CD204+ cells from 
the PV using flow cytometory. Blood samples from the PV of 
the resected lungs were obtained from 106 NSCLC patients 
who underwent complete resection with a lobectomy or a more 
extensive surgery between December 2009 and April 2010 at 
our hospital. Among these patients, patients who underwent 
preoperative chemotherapy, radiation therapy, or both were 
not included. Representative data for two flow cytometry anal-
yses are shown in Figure 3A for tumors with the low and high 
number of CD14+CD204+ blood mononuclear cells from the 
PV. The median count for all 106 patients was 14,500, with 
an interquartile range of 200 to 7,539,648 per 1 mm3 blood 
from the PV. We also performed immunohistochemical stain-
ing for CD204 in these 106 tumor specimens and counted the 
CD204+ macrophages in the stroma of the tumor. The number 
of CD14+CD204+ cells from the PV was found to be corre-
lated with the number of CD204+ macrophages identified in 
the stroma of the tumor (Fig. 3B). When a total of 106 lung 
cancer patients were classified into two groups with a high 
or a low number of CD14+CD204+ cells from the PV based 
on the median number of CD14+CD204+ cells for the entire 
group, a significantly greater number of CD204+ macrophages 
in the stroma were observed among the patients with high lev-
els of CD14+CD204+ cells from the PV (p < 0.01; Fig. 3C). 
In addition, significantly more cases with a high number of 
CD14+CD204+ cells from the PV developed early recurrence 
within 2 years after resection (2-year recurrence-free prob-
ability: 76.6% and 94.2%, respectively; p < 0.01; Fig. 3D). 
Because postoperative recurrences develop more frequently 
among patients with high levels of CD14+CD204+ cells from 
the PV, we speculated that these circulating CD14+CD204+ 
cells might affect postoperative recurrences.
CD14+CD204+ Cells Promote the Metastasis 
of Cancer Cells In Vivo Model
We assessed the invasive capacity of cancer cells with 
or without the CD14+CD204+ macrophages using a matrigel 
TABLE 1.  Patient Characteristics and Univariate Analysis 
of Risk Factors for Recurrence in Stage I Adenocarcinoma 
Patients
Characteristics
No. of Patients 
(%)
Three-Year 
Recurrence-Free 
Probability (%)
Univariate  
p Value by  
Log-Rank Test
Overall 207 90.1
Age (yrs)
  ≤63 105 (51) 93.2 0.106
  >63 102 (49) 87.1
Sex
  Women 113 (55) 96.4 <0.01
  Men 94 (45) 82.2
Smoking history
  Never smoker 99 (48) 94.9 0.246
  Ever smoker 108 (52) 85.6
Tumor size (cm)
  ≤2.0 81 (39) 97.5 <0.01
  >2.0 126 (61) 84.4
Number of 204+ cells in the resected specimen
  Low 105 (51) 98 <0.01
  High 102 (49) 82.1
Stage
  IA 138 (67) 96.3 <0.01
  IB 69 (33) 77.8
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invasion assay. A549 cells were seeded into the upper cham-
ber 30 minutes after the addition of the medium alone, or in 
combination with the CD14+CD204− cells, or in combination 
with the CD14+CD204+ cells (Figure 4A). After a 22-hour 
incubation period, a significantly increased number of invad-
ing A549 cells on the lower surface of the filters was identified 
when CD14+CD204+ cells were added before the addition of 
the A549 cells, relative to the addition of the medium alone 
or the addition of the CD14+CD204− cells (p < 0.05, respec-
tively; Fig. 4A).
We next examined whether these CD14+CD204+ cells 
promoted the metastasis of cancer cells. Because lung colo-
nization of cancer cells injected through the tail vein of mice 
is widely used as a model for detecting metastasis, we used 
this experimental model to assess whether CD14+CD204+ 
cells promote the metastasis of cancer cells more effec-
tively than CD14+CD204− cells. After dividing the mice into 
three groups, we injected one group with the medium alone, 
another group with CD14+CD204− cells, and the remaining 
group with CD14+CD204+ cells. Thirty minutes later, we con-
tinuously injected 5 × 104 of A549 cancer cells into each of 
the mice in the three groups through a different tail vein. A 
statistically significant increase in the total number of met-
astatic lesions was observed 30 days after the injections in 
the CD14+CD204+ cell group compared with the numbers 
in the other two groups (p < 0.05, respectively; Fig. 4B). 
Immunohistochemical staining was also performed for met-
astatic lesions using mouse anti-human CD204 antibody. 
CD204+ cells were identified only in the metastatic lesions of 
the CD14+CD204+ cell group (Fig. 4B).
FIGURE 3.  Correlation among the number of CD204+ macrophages infiltrating the stroma of the primary tumor, the number 
of CD14+CD204+ cells from the PV, and the probability of postoperative recurrence in lung cancer patients. A, Quantification of 
CD14+CD204+ cells among blood mononuclear cells from the PV. Representative data for two flow cytometry analyses. B, The 
number of CD14+CD204+ cells from the PV is correlated with the number of CD204+ macrophages in the stroma of the primary 
tumor. R = 0.658. *p < 0.05. C, A significantly greater number of CD204+ macrophages in the stroma are observed among the 
patients with high levels of CD14+CD204+ cells from the PV. D, Significantly more cases with a high number of CD14+CD204+ 
cells from the PV develop early recurrence within 2 years after resection (p < 0.01). PV, pulmonary vein.
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Because we suspected that factors derived from the 
CD14+CD204+ cells may facilitate the metastasis of cancer 
cells, a genome-wide screening for genes with different expres-
sion patterns between CD14+CD204− cells and CD14+CD204+ 
cells was performed using a microarray. Table 2 shows the 
representative genes that were differentially expressed in the 
CD14+CD204− and CD14+CD204+ cells.
Prognostic Impact of the Number of 
Circulating CD14+CD204+ Cells from 
the PV on Resected NSCLC Patients
Table 3 shows the number of circulating CD14+CD204+ 
cells from the PV according to the clinicopathological fea-
tures of 106 NSCLC patients. Statistically significant 
TABLE 2.  Representative Genes Differentially Expressed in 
CD14+CD204− and CD14+CD204+ Cells
Ratio
Genes up-regulated in CD14±CD204± cells
  Membrane receptors
   CD206 70
   CD204 8
   Interleukin 1 receptor 7
   CD163 5
  Extracellular mediator
   Vascular endothelial growth factor B 30
   Fibronectin 1 9
   Transforming growth factor α–induced protein 6
   Platelet-derived growth factor C 6
  Matrix-degrading enzymes
   MMP7 563
   MMP9 388
   MMP12 175
   MMP2 10
   MMP19 10
   MMP8 5
  Apoptosis-related genes
   Growth arrest and DNA-damage–inducible protein gamma 7
  Cytokines and chemokines
   CCL13 1488
   CCL7 793
   CCL18 458
   CXCL13 226
   CCL2 160
   CCL8 148
   CCL22 140
   CCL23 79
   CXCL5 30
   Colony-stimulating factor 1 22
   CCL20 21
   CXCL1 17
   CCL17 11
   CXCL9 9
   CXCL2 8
   Interleukin 10 7
   Tumor necrosis factor ligand superfamily, member 2 6
   Interleukin 6 5
Genes down-regulated in CD14±CD204± cells
  Membrane receptors
   CD97 0.14
   CD93 0.14
   CXCR4 0.07
  Extracellular mediator
   Hepatocyte growth factor 0.2
   Insulin-like growth factor–binding protein 3 0.17
  Apoptosis-related genes
   Growth arrest and DNA-damage–inducible protein-β 0.17
   Bcl-2–associated X protein 0.11
TABLE 3.  Correlation between Clinicopathological 
Characteristics and Number of CD14+204+ Cells from the PV 
in 106 Resected Non–Small-Cell Lung Cancer Patients
Characteristics
No. of  
Patients 
(%)
No. of CD14+204+ 
Cells in the PV  
(/ml) ± SE p
Total 106 38,699 ± 7061
Age (yrs)
  ≤68 55 (52) 39,162 ± 8856 0.946
  >68 51 (48) 38,199 ± 11,237
Sex
  Women 33 (31) 22,941 ± 6010 0.04
  Men 73 (69) 45,822 ± 9801
Smoking history
  Never smoker 35 (33) 24,075 ± 6160 0.147
  Ever smoker 71 (67) 45,908 ± 10,016
Histological type
  Nonadenocarcinoma 40 (38) 50,355 ± 11,545 0.2
  Adenocarcinoma 66 (62) 31,635 ± 8880
Tumor size (cm)
  ≤3.0 68 (64) 21,929 ± 3496 <0.001
  >3.0 38 (36) 68,708 ± 17,809
N status
  N0 83 (88) 30,574 ± 7366 0.028
  N1-3 23 (22) 68,020 ± 17,860
Stage
  IA 56 (53) 19,549 ± 2966 0.004
  IB or higher 50 (47) 99,420 ± 14,060
PV, pulmonary vein; SE, standard error.
   Caspase2 0.1
  Cytokines and chemokines
   Interleukin1β 0.17
Oligonucleotide microarray search for genes differently expressed in CD14+CD204+ 
cells compared with CD14+CD204− cells.
MMP, matrix metalloprotease; CCL, C-C motif chemokine ligand; CXCL, C-X-C 
motif chemokine ligand.
TABLE 2.  Continued
Ratio
(Continued)
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correlations were observed between the number of circulat-
ing CD14+CD204+ cells from the PV and the patient sex, 
tumor size, N status, or stage (Table 3). Table 4 lists the 2-year 
recurrence-free probabilities according to clinicopathological 
features. Univariate analysis identified the following three sta-
tistically significant risk factors for recurrence: the number of 
CD14+CD204+ cells from the PV, lymph node involvement, 
and tumor stage. In multivariate analysis, only the high num-
ber of CD14+CD204+ cells from the PV was found to be a 
statistically significant independent risk factor for early recur-
rence (p < 0.05; Table 4).
DISCUSSION
The invasion of cancer cells into intratumoral blood ves-
sels in the primary tumor is often observed in resected lung 
cancer tissue.2 The intratumoral vessel invasion of cancer cells 
has been reported to be significantly correlated with the post-
operative recurrence and an unfavorable prognosis.2 This find-
ing indicates that cancer cells mobilize into the bloodstream 
and circulate, resulting in postoperative distant metastasis. In 
this study, we observed that CD204+ tumor–associated mac-
rophages were found not only in the stroma of the tumor but 
also in intratumoral blood vessels (Fig. 2C). This finding raises 
the possibility that CD204+ macrophages in the primary tumor 
mobilize into the bloodstream and circulate, in addition to the 
circulating cancer cells. The results of this study showed that 
the number of CD14+CD204+ cells from the PV was found to 
be significantly correlated with the number of CD204+ mac-
rophages identified in the stroma of the tumor. We consid-
ered that educated CD14+ CD204− cells become polarized to 
CD14+CD204+ cells at the primary tumor site and are subse-
quently mobilized into the bloodstream and circulate. In addi-
tion, postoperative recurrences develop more frequently among 
patients with high levels of CD14+CD204+ cells from the PV in 
our clinical data. Also in our in vivo model, we demonstrated 
that CD14+CD204+ cells facilitated the metastasis of cancer 
cells more effectively than CD14+CD204− cells. From these 
results, we suggest the concept that tumor-associated macro-
phages remote from the primary tumor and directly contribute 
to the metastasis of cancer cells at distant sites (Fig. 4C).
Although surgery effectively controls many cancers at 
the primary site, the development of metastatic disease after 
an operation signals a poor prognosis. In lung cancer patients, 
many patients with completely resected tumors eventually 
die as a result of metastatic disease occurring after resec-
tion.2 To prevent postoperative distant metastases, adjuvant 
TABLE 4.  Univariate and Multivariate Analyses of Risk Factors for Recurrence in 106 Resected Non–Small-Cell Lung Cancer 
Patients
Characteristics
No. of  
Patients 
(%)
Two-Year 
Recurrence-Free 
Probability (%)
Univariate  
p Value by  
Log-Rank Test
Multivariate Analysis
HR 95% CI p
Overall 106 56.1
Age (yrs)
  ≤68 55 (52) 85.0 0.881 Not included multivariable model
  >68 51 (48) 85.9
Sex
  Women 33 (31) 87.5 0.432 Not included multivariable model
  Men 73 (69) 84.6
Smoking history
  Never smoker 35 (33) 88.3 0.703 Not included multivariable model
  Ever smoker 71 (67) 84.1
Histological type
  Nonadenocarcinoma 40 (38) 85.0 0.961 Not included multivariable model
  Adenocarcinoma 66 (62) 85.7
Tumor size (cm)
  ≤3.0 68 (64) 88.1 0.298 Not included multivariable model
  >3.0 38 (36) 80.6
Number of CD14+204+ cells in the PV
  ≤14,500/ml 53 (50) 94.2 0.0098 1
  >14,500/ml 53 (50) 76.6 3.193 1.025–9.944 0.045
N status
  N0 83 (88) 91.3 0.0043 1
  N1-3 23 (22) 69.6 2.205 0.658–7.387 0.200
Stage
  IA 56 (53) 92.8 0.038 1
  IB or higher 50 (47) 76.9 1.443 0.406–7.387 0.571
PV, pulmonary vein; HR, hazard ratio; CI, confidence interval.
187Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 2, February 2014 Circulating CD14+CD204+ Cells
chemotherapy is recommended to eliminate occult metasta-
ses19,20 and postoperative adjuvant cisplatin-based chemother-
apy has recently become the standard of care.19,20 However, the 
reported reduction of the relative risk of mortality was only 
estimated to be 11% to 13%,19,20 and the effect of conventional 
postoperative adjuvant chemotherapy targeting only the can-
cer cells is not satisfactory.
Tumor metastasis consists of a series of discrete biological 
processes which move tumor cells from the primary tumor to a 
distant location. Tumor cells must invade the tissue surrounding 
FIGURE 4.  CD14+CD204+ cells facilitated the lung metastasis of cancer cells more effectively than CD14+CD204− cells. A, 
Matrigel invasion assay. A significantly increased number of invading A549 cells on the lower surface of the filters is identified 
when CD14+CD204+ cells are added. *p < 0.05. B, CD14+CD204+ cells promote the metastasis of A549 cancer cells. *p < 0.05. 
C, Our concept that CD204+ tumor–associated macrophages remote from the primary tumor directly contribute to the metasta-
sis of cancer cells at distant sites.
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the primary tumor, enter either the lymphatic system or the blood-
stream where they survive, and eventually become arrested from 
circulation. Then, these cells extravasate into tissues and grow at 
the new site. The term “colonization” is frequently used to reflect 
the combined influences of tumor cell proliferation, dormancy, 
and angiogenesis in the formation of a progressively growing 
lesion at a distant site. Thus far, there have been several reports 
on the role of stromal cells in aiding tumor colonization of dis-
tant organs.21,22 Hiratsuka et al.21 provided evidence suggesting 
that the activation of lung macrophages by primary Lewis lung 
carcinoma tumors enhances lung metastasis in a model of exper-
imental metastasis. Kaplan et al.22 also reported that the bone 
marrow-derived vascular endothelial growth factor receptor 1+ 
hematopoietic cells show characteristics common to physiologi-
cal pathways of inflammation by providing the necessary growth 
conditions to create a conductive microenvironment in the lungs 
for the engraftment of tumor cells. These studies21,22 have shown 
that the efficiency of the metastatic process may be increased by 
some stromal cells. Therefore, a more detailed understanding of 
the efficiency of the metastatic process of cancer cells, including 
the involvement of stromal cells in colonization, is likely to con-
tribute to the development of better postoperative therapies and 
to improve patient outcomes after lung cancer resection. In this 
study, early recurrences were found to develop more frequently 
in tumors with high levels of CD14+CD204+ cells from the PV. 
In addition, CD14+CD204+ cells, which were polarized to the 
tumor-promoting phenotype cultured in lung cancer cell line–
conditioned medium, facilitated the lung metastasis of cancer 
cells more effectively than CD14+CD204− cells in our in vivo 
mouse model. These results may indicate a need for treatment 
that targets for circulating CD14+CD204+ cells to prevent post-
operative recurrence in addition to cancer cells. Hiratsuka et al.21 
demonstrated that the primary tumors themselves induce matrix 
 metalloprotease-9 (MMP9) expression in the macrophages of 
the metastatic site, thereby promoting the invasion of cancer 
cells. It was found that blockage of MMP9 induction could 
be useful for the prevention of tumor metastasis.21 Also in the 
present study, the expression of MMP9 on the CD14+CD204+ 
cells was up-regulated compared with the expression levels in 
the CD14+CD204− cells. To explore the role of CD14+CD204+ 
cells in facilitating the metastasis of cancer cells relative to 
CD14+CD204− cells, we will focus on the increased expression 
of MMP9 on CD14+CD204+ cells in the future study.
CONCLUSION
Our results showed the possibility that circulating 
CD14+CD204+ cells contribute to the metastasis of cancer cells. 
The blockage of circulating CD14+CD204+ cells activity may 
prevent postoperative recurrence in resected NSCLC patients.
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